Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 9 results:
[ Συντάκτης(Desc)] Τίτλος Τύπος Έτος
Φίλτρα: Συντάκτης is Makras, Polyzois  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
M
Makras, P., Anastasilakis A. D., Polyzos S. A., Bisbinas I., Sakellariou G. T., & Papapoulos S. E. (2011).  No effect of rosuvastatin in the zoledronate-induced acute-phase response.. Calcif Tissue Int. 88(5), 402-8.
Makras, P., Polyzos S. A., & Anastasilakis A. D. (2016).  Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid.. J Clin Endocrinol Metab. 101(9), L89-90.
Makras, P., Yavropoulou M. P., Polyzos S. A., Papapoulos S. E., Georgakopoulou D., Papatheodorou A., et al. (2023).  The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection.. Osteoporos Int.
Makras, P., Polyzos S. A., Papatheodorou A., Kokkoris P., Chatzifotiadis D., & Anastasilakis A. D. (2013).  Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis.. Clin Endocrinol (Oxf). 79(4), 499-503.
Makras, P., Appelman-Dijkstra N. M., Papapoulos S. E., van Wissen S., Winter E. M., Polyzos S. A., et al. (2021).  The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation.. J Clin Endocrinol Metab.
Makras, P., Polyzos S. A., Anastasilakis A. D., Terpos E., Kanakis G., Schini M., et al. (2012).  Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosis.. J Clin Endocrinol Metab. 97(4), E618-21.
Makras, P., Babis G. C., Chronopoulos E., Karachalios T., Kazakos K., Paridis D., et al. (2020).  Experience gained from the implementation of the fracture liaison service in Greece.. Arch Osteoporos. 15(1), 12.
Makras, P., Polyzos S. A., Anastasilakis A. D., Terpos E., Papatheodorou A., & Kaltsas G. A. (2012).  Is serum IL-17A a useful systemic biomarker in patients with Langerhans cell histiocytosis?. Mol Ther. 20(1), 6-7.
Makras, P., Papapoulos S. E., Polyzos S. A., Appelman-Dijkstra N. M., & Anastasilakis A. D. (2020).  The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.. Bone. 138, 115478.

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές